Home / Intelligence

  • All
  • Blog
  • Briefs
  • Case Studies
  • Industry Publications
  • Podcasts
  • Scientific Publications
  • Webinars
  • White Papers

Building Commercial Teams

Watch our webinar recording of Curt Staab, Sr. Vice President of Emerging Life Sciences Network as he draws from the latest landscape findings about how biopharma companies are finding talent, interviewing candidates and building commercial teams under the constraints of working during the pandemic. We explore how biopharma companies are finding talent, interviewing candidates and building commercial teams under the constraints of working during the COVID-19 pandemic.…

Watch Now

Webinar Recording: Tenth Annual Incentive Compensation Landscape

A Biopharma Industry Perspective on the Current and Future State of Incentive Compensation Trinity Life Sciences shares highlights from our latest TGaS Landscape report entitled, “Tenth Annual Incentive Compensation Landscape.” This highly anticipated report is based on interviews of 38 biopharmaceutical incentive compensation (IC) leaders who shared their experiences on IC planning. The Tenth Annual edition is perhaps more critical than ever before as companies adapt IC approaches and plan amid COVID-19 challenges. From implementing COVID-specific Management by Objective (MBO)…

Watch Now

Data Management Advisory Brief

Trinity has heard numerous organizations express frustration with their data management provider. Common challenges include quality issues, timeliness and lack of flexibility. Switching to another provider isn’t as hard as you think. In this advisory brief, we outline the top five things to keep in mind if you are considering a switch. Please complete the form to download a copy of our Advisory Brief: Frustrated with Your Current Data Management Provider?…

Read Now

Real-World Evidence Webinar

Realizing the Value of RWE Data… Faster Biopharmaceutical companies recognize the value of RWE and strive to make it a routine part of their decision-making process. Many face challenges, however, with optimizing their use of RWE data in the earlier stages of commercial planning and in life-cycle management. Disparate, error-prone, costly data coupled with a lack of time, resources, or experience generating insights lead to elongated project timelines.During this webinar, we will discuss barriers to RWE use in commercialization planning…

Watch Now

Launching During COVID-19 Whitepaper

What is and isn’t working for drug launches amid COVID-19? Six months after COVID-19 lock-downs began, Trinity has uncovered some surprising (and some concerning) answers to key questions everyone is asking. In this paper, we examine the trajectory of new molecular entities (NMEs) approved in late 2019 and early 2020 to understand how to drive a successful drug launch (and avoid the pitfalls) in the age of COVID-19.…

Read Now

Systemic Literature Review to Characterize the Burden and Unmet Needs Associated with Cremophor EL

Cremophor EL (CrEL) is an additive (excipient) used to improve the solubility of hydrophobic drugs including certain anti-cancer drugs, like paclitaxel. Although the potential toxicities associated with CrEL are well known, the burden of CrEL-containing therapy is not well defined in the published scientific literature. Authors Brixner D, McKinley K, Gelder M, Oak B, Dehipawala S, Hadker N Journal ISPOR Meeting 2021 View publication…

Read Now

Evaluating Health-Related Quality of Life (HRQoL) in Patients with and without Crohn’s Perianal Fistulas (CPF) Using the Euroqol Five-Dimension (EQ-5D-5L) Questionnaire in a Real-World US Setting

Crohn’s disease (CD) substantially impacts HRQoL, with complications such as perianal fistulas potentially increasing burden of illness. We investigated HRQoL in patients with CD and CPF and those without CPF, and for patients with CPF with and without CPF-related surgery. Authors Jiang J, Kuharic M, Athavale A, Fan T, Silber A, Abilash V, Hadker N, Sharpe E, Cazzetta S Journal ISPOR Meeting 2021 View publication…

Read Now

Risk Factors Associated with Recurrence and Corticosteroid-Associated Adverse Events in Patients with Recurrent Pericarditis

Recurrent pericarditis (RP) occurs in up to 30% of acute pericarditis patients with some experiencing multiple recurrences and/or complications. Treating RP with corticosteroids can increase adverse events, risk of recurrence, and potentially healthcare resource utilization. This retrospective study examined risk factors for recurrence and corticosteroid-related adverse events (CS-AEs) among RP patients. Authors Schwier NC, Luis SA, Hu X, Athavale A, Skaar J, Magestro M, Lim-Watson M Journal ISPOR Meeting 2021 View publication…

Read Now

Clinical and Economic Impact of Primary Hyperoxaluria: A Retrospective Claims Analysis

Primary hyperoxalurias (PH; types 1, 2, and 3) are rare genetic disorders resulting in the overproduction of oxalate in the liver and that manifest in renal complications. This study sought to quantify the healthcare resource utilization (HCRU), costs, and clinical characteristics of PH patients. Authors Bernd Hoppe, Abigail Silber, Gavin Miyasato, Tom Koenig, Jeffrey Skaar, Craig Langman Journal American Society of Nephrology; ASN Kidney Week 2020 View publication…

Read Now

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email